Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
2 files | 4.60 MB
Add to list
  1. Search results
  2. Position paper on the reporting of no...

Position paper on the reporting of norepinephrine formulations in critical care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force

Patrick M. Wieruszewski, Marc Leone, Benjamin Skov Kaas-Hansen, Siddharth Dugar, Matthieu Legrand, Cathrine A. McKenzie, Brittany D. Bissell Turpin, Antonio Messina, Prashant Nasa, Christa A. Schorr, et al.
(2024) CRITICAL CARE MEDICINE. 52(4). p.521-530
Author
Organization
Project
Abstract
OBJECTIVES: To provide guidance on the reporting of norepinephrine formulation labeling, reporting in publications, and use in clinical practice. DESIGN: Review and task force position statements with necessary guidance. SETTING: A series of group conference calls were conducted from August 2023 to October 2023, along with a review of the available evidence and scope of the problem. SUBJECTS: A task force of multinational and multidisciplinary critical care experts assembled by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine. INTERVENTIONS: The implications of a variation in norepinephrine labeled as conjugated salt (i.e., bitartrate or tartrate) or base drug in terms of effective concentration of norepinephrine were examined, and guidance was provided. MEASUREMENTS AND MAIN RESULTS: There were significant implications for clinical care, dose calculations for enrollment in clinical trials, and results of datasets reporting maximal norepinephrine equivalents. These differences were especially important in the setting of collaborative efforts across countries with reported differences. CONCLUSIONS: A joint task force position statement was created outlining the scope of norepinephrine-dose formulation variations, and implications for research, patient safety, and clinical care. The task force advocated for a uniform norepinephrine-base formulation for global use, and offered advice aimed at appropriate stakeholders.
Keywords
hypotension, norepinephrine, patient safety, research methods, shock, vasopressor, CAMPAIGN INTERNATIONAL GUIDELINES, SEPTIC SHOCK, SERIAL EVALUATION, SOFA SCORE, MORTALITY, SEPSIS, MANAGEMENT, VASOPRESSORS, INFUSION

Downloads

  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.62 MB
  • Download
    Wieruszewski P et al Accepted Manuscript.pdf
    • full text (Accepted manuscript)
    • |
    • open access
    • |
    • PDF
    • |
    • 2.98 MB

Citation

Please use this url to cite or link to this publication:

MLA
Wieruszewski, Patrick M., et al. “Position Paper on the Reporting of Norepinephrine Formulations in Critical Care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force.” CRITICAL CARE MEDICINE, vol. 52, no. 4, 2024, pp. 521–30, doi:10.1097/ccm.0000000000006176.
APA
Wieruszewski, P. M., Leone, M., Kaas-Hansen, B. S., Dugar, S., Legrand, M., McKenzie, C. A., … Khanna, A. K. (2024). Position paper on the reporting of norepinephrine formulations in critical care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force. CRITICAL CARE MEDICINE, 52(4), 521–530. https://doi.org/10.1097/ccm.0000000000006176
Chicago author-date
Wieruszewski, Patrick M., Marc Leone, Benjamin Skov Kaas-Hansen, Siddharth Dugar, Matthieu Legrand, Cathrine A. McKenzie, Brittany D. Bissell Turpin, et al. 2024. “Position Paper on the Reporting of Norepinephrine Formulations in Critical Care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force.” CRITICAL CARE MEDICINE 52 (4): 521–30. https://doi.org/10.1097/ccm.0000000000006176.
Chicago author-date (all authors)
Wieruszewski, Patrick M., Marc Leone, Benjamin Skov Kaas-Hansen, Siddharth Dugar, Matthieu Legrand, Cathrine A. McKenzie, Brittany D. Bissell Turpin, Antonio Messina, Prashant Nasa, Christa A. Schorr, Jan De Waele, and Ashish K. Khanna. 2024. “Position Paper on the Reporting of Norepinephrine Formulations in Critical Care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force.” CRITICAL CARE MEDICINE 52 (4): 521–530. doi:10.1097/ccm.0000000000006176.
Vancouver
1.
Wieruszewski PM, Leone M, Kaas-Hansen BS, Dugar S, Legrand M, McKenzie CA, et al. Position paper on the reporting of norepinephrine formulations in critical care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force. CRITICAL CARE MEDICINE. 2024;52(4):521–30.
IEEE
[1]
P. M. Wieruszewski et al., “Position paper on the reporting of norepinephrine formulations in critical care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force,” CRITICAL CARE MEDICINE, vol. 52, no. 4, pp. 521–530, 2024.
@article{01HQTP6BTQ2PXDSN138BKP60TG,
  abstract     = {{OBJECTIVES: 
To provide guidance on the reporting of norepinephrine formulation labeling, reporting in publications, and use in clinical practice.

DESIGN: 
Review and task force position statements with necessary guidance.

SETTING: 
A series of group conference calls were conducted from August 2023 to October 2023, along with a review of the available evidence and scope of the problem.

SUBJECTS: 
A task force of multinational and multidisciplinary critical care experts assembled by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine.

INTERVENTIONS: 
The implications of a variation in norepinephrine labeled as conjugated salt (i.e., bitartrate or tartrate) or base drug in terms of effective concentration of norepinephrine were examined, and guidance was provided.

MEASUREMENTS AND MAIN RESULTS: 
There were significant implications for clinical care, dose calculations for enrollment in clinical trials, and results of datasets reporting maximal norepinephrine equivalents. These differences were especially important in the setting of collaborative efforts across countries with reported differences.

CONCLUSIONS: 
A joint task force position statement was created outlining the scope of norepinephrine-dose formulation variations, and implications for research, patient safety, and clinical care. The task force advocated for a uniform norepinephrine-base formulation for global use, and offered advice aimed at appropriate stakeholders.}},
  author       = {{Wieruszewski, Patrick M. and Leone, Marc and Kaas-Hansen, Benjamin Skov and Dugar, Siddharth and Legrand, Matthieu and McKenzie, Cathrine A. and Bissell Turpin, Brittany D. and Messina, Antonio and Nasa, Prashant and Schorr, Christa A. and De Waele, Jan and Khanna, Ashish K.}},
  issn         = {{0090-3493}},
  journal      = {{CRITICAL CARE MEDICINE}},
  keywords     = {{hypotension,norepinephrine,patient safety,research methods,shock,vasopressor,CAMPAIGN INTERNATIONAL GUIDELINES,SEPTIC SHOCK,SERIAL EVALUATION,SOFA SCORE,MORTALITY,SEPSIS,MANAGEMENT,VASOPRESSORS,INFUSION}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{521--530}},
  title        = {{Position paper on the reporting of norepinephrine formulations in critical care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force}},
  url          = {{http://doi.org/10.1097/ccm.0000000000006176}},
  volume       = {{52}},
  year         = {{2024}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: